THREAD: @iampinkywebb speaks to Sinovac Biotech General Manager Helen Yang on #TheSource | LIVE https://t.co/9vB0Rjs8f8

• Senators question gov't deal with China's COVID-19 vaccine, Sinovac
• Palace: Sinovac price not far from ₱650
• Why should Filipinos consider getting it?

Sinovac Biotech on vaccine deal with PH gov't: We are finalizing the term sheet. It's a non-binding understanding between the buyers and sellers.

Sinovac Biotech adds the deal is not yet sealed.
Sinovac Biotech: FDA should approve the vaccine first
Sinovac Biotech says they have already started producing the vaccine in commercial size late last year
Sinovac Biotech on cost of vaccine: Buying the vaccine is only one factor. Logistics and other factors should also be considered.
Sinovac Biotech on cost of vaccine: We gave a very good price for the Philippines
Sinovac Biotech refuses to comment on the cost of its vaccine, but says it's not among the expensive vaccines.

"The pricing is reasonable," General Manager Helen Yang says.
RELATED: Presidential Spokesperson Harry Roque said Sinovac's CoronaVac is priced near ₱650 per dose or ₱1300 for the complete two doses https://t.co/QvvMVC3uqf
Sinovac Biotech: Clinical phase 3 trials being conducted in Indonesia, Brazil, Turkey
Sinovac Biotech says the vaccine can protect people from severe cases of infection
Sinovac Biotech: We think efficacy rating will be higher among general population
Sinovac Biotech: Our safety profile is very good. The pain, as reported by our partners in other countries, was felt by around 20% of people when they were injected.
Sinovac Biotech: We're willing to supply additional documents required by FDA for emergency use authorization (EUA)
RELATED: Sinovac applied for EUA on Wednesday, but submitted incomplete documents, FDA Director General Domingo says https://t.co/YD032AGh27
Sinovac Biotech: 8 million doses of our vaccine have been rolled out in China

More from World

You May Also Like

So the cryptocurrency industry has basically two products, one which is relatively benign and doesn't have product market fit, and one which is malignant and does. The industry has a weird superposition of understanding this fact and (strategically?) not understanding it.


The benign product is sovereign programmable money, which is historically a niche interest of folks with a relatively clustered set of beliefs about the state, the literary merit of Snow Crash, and the utility of gold to the modern economy.

This product has narrow appeal and, accordingly, is worth about as much as everything else on a 486 sitting in someone's basement is worth.

The other product is investment scams, which have approximately the best product market fit of anything produced by humans. In no age, in no country, in no city, at no level of sophistication do people consistently say "Actually I would prefer not to get money for nothing."

This product needs the exchanges like they need oxygen, because the value of it is directly tied to having payment rails to move real currency into the ecosystem and some jurisdictional and regulatory legerdemain to stay one step ahead of the banhammer.